Proteomic signature for detection of high-grade ovarian cancer in germline BRCA mutation carriers.
BRCA
early detection biomarker
ovarian cancer
utero-tubal lavage
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 02 2023
15 02 2023
Historique:
revised:
21
08
2022
received:
15
03
2022
accepted:
05
09
2022
pubmed:
11
10
2022
medline:
28
12
2022
entrez:
10
10
2022
Statut:
ppublish
Résumé
No current screening methods for high-grade ovarian cancer (HGOC) guarantee effective early detection for high-risk women such as germline BRCA mutation carriers. Therefore, the standard-of-care remains risk-reducing salpingo-oophorectomy (RRSO) around age 40. Proximal liquid biopsy is a promising source of biomarkers, but sensitivity has not yet qualified for clinical implementation. We aimed to develop a proteomic assay based on proximal liquid biopsy, as a decision support tool for monitoring high-risk population. Ninety Israeli BRCA1 or BRCA2 mutation carriers were included in the training set (17 HGOC patients and 73 asymptomatic women), (BEDOCA trial; ClinicalTrials.gov Identifier: NCT03150121). The proteome of the microvesicle fraction of the samples was profiled by mass spectrometry and a classifier was developed using logistic regression. An independent cohort of 98 BRCA mutation carriers was used for validation. Safety information was collected for all women who opted for uterine lavage in a clinic setting. We present a 7-protein diagnostic signature, with AUC >0.97 and a negative predictive value (NPV) of 100% for detecting HGOC. The AUC of the biomarker in the independent validation set was >0.94 and the NPV >99%. The sampling procedure was clinically acceptable, with favorable pain scores and safety. We conclude that the acquisition of Müllerian tract proximal liquid biopsies in women at high-risk for HGOC and the application of the BRCA-specific diagnostic assay demonstrates high sensitivity, specificity, technical feasibility and safety. Similar classifier for an average-risk population is warranted.
Substances chimiques
BRCA1 Protein
0
Banques de données
ClinicalTrials.gov
['NCT03150121']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
781-793Informations de copyright
© 2022 UICC.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.
Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet (London, England). 2021;397:2182-2193.
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402.
Rosenthal AN, Fraser LSM, Philpott S, et al. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study. J Clin Oncol. 2017;35(13):1411-1420.
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing Salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. JNCI J Natl Cancer Inst. 2009;101(2):80-87.
Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609-1615.
Kotsopoulos J, Gronwald J, Karlan B, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2018;150(1):85-91.
Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26(32):5284-5293.
Perets R, Drapkin R. It's totally tubular.…Riding the new wave of ovarian cancer research. Cancer Res. 2016;76(1):10-17.
Morrison JC, Blanco LZ, Vang R, Ronnett BM. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting analysis of a case series. Am J Surg Pathol. 2015;39(4):442-453.
Bijron J, Seldenrijk C, Zweemer R, Lange J, Verheijen R, van Diest P. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol. 2013;37(8):1123-1130.
Patrono MG, Iniesta MD, Malpica A, et al. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review. Gynecol Oncol. 2015;139(3):568-572.
Soong TR, Howitt BE, Horowitz N, Nucci MR, Crum CP. The fallopian tube, “precursor escape” and narrowing the knowledge gap to the origins of high-grade serous carcinoma. Gynecol Oncol. 2019;152(2):426-433.
Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8(1):1093.
George SHL, Greenaway J, Milea A, et al. Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers. J Pathol. 2011 Sep;225(1):106-117.
Brouwer J, Kluiver J, de Almeida R, et al. Small RNA sequencing reveals a comprehensive miRNA signature of BRCA1-associated high-grade serous ovarian cancer. J Clin Pathol. 2016;69(11):979-985.
Veskimäe K, Staff S, Tabaro F, Nykter M, Isola J, Mäenpää J. Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies. Genes Chromosomes Cancer. 2015;54(5):276-287.
Tone AA, Begley H, Sharma M, et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res. 2008;14(13):4067-4078.
Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5(167):167ra4.
Maritschnegg E, Wang Y, Pecha N, et al. Lavage of the uterine cavity for molecular detection of Müllerian duct carcinomas: a proof-of-concept study. J Clin Oncol. 2015;33(36):4293-4300.
Krimmel-Morrison JD, Ghezelayagh TS, Lian S, et al. Characterization of TP53 mutations in pap test DNA of women with and without serous ovarian carcinoma. Gynecol Oncol. 2020;156(2):407-414.
Wang Y, Li L, Douville C, et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med. 2018;10(433):eaap8793.
Maritschnegg E, Heitz F, Pecha N, et al. Uterine and tubal lavage for earlier cancer detection using an innovative catheter: a feasibility and safety study. Int J Gynecol Cancer. 2018;28(9):1692-1698.
Barnabas GDGD, Bahar-Shany K, Sapoznik S, et al. Microvesicle proteomic profiling of uterine liquid biopsy for ovarian cancer early detection. Mol Cell Proteomics. 2019;18(5):865-875.
Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404.
Bernstein-Molho R, Friedman E, Kedar I, et al. Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants. Breast Cancer Res Treat. 2020;181(2):445-453.
Abaza A, Soleilhac JM, Westendorf J, et al. M phase phosphoprotein 1 is a human plus-end-directed kinesin-related protein required for cytokinesis. J Biol Chem. 2003;278(30):27844-27852.
Chen J, Zhao CC, Chen FR, Feng GW, Luo F, Jiang T. KIF20B promotes cell proliferation and may be a potential therapeutic target in pancreatic cancer. J Oncol. 2021;1-11.
Lin WF, Lin XL, Fu SW, et al. Pseudopod-associated protein KIF20B promotes Gli1-induced epithelial-mesenchymal transition modulated by pseudopodial actin dynamic in human colorectal cancer. Mol Carcinog. 2018;57(7):911-925.
Kanehira M, Katagiri T, Shimo A, et al. Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. Cancer Res. 2007;67(7):3276-3285.
Wartosch L, Günesdogan U, Graham SC, Luzio JP. Recruitment of VPS33A to HOPS by VPS16 is required for lysosome fusion with endosomes and autophagosomes. Traffic. 2015;16(7):727-742.
Zhang W, Zhang X, Huang S, et al. FOXM1D potentiates PKM2-mediated tumor glycolysis and angiogenesis. Mol Oncol. 2021;15(5):1466-1485.
Segala G, Bennesch MA, Ghahhari NM, et al. Vps11 and Vps18 of Vps-C membrane traffic complexes are E3 ubiquitin ligases and fine-tune signalling. Nat Commun. 2019;10(1):1833.
Steck E, Bräun J, Pelttari K, Kadel S, Kalbacher H, Richter W. Chondrocyte secreted CRTAC1: a glycosylated extracellular matrix molecule of human articular cartilage. Matrix Biol. 2007;26(1):30-41.
Yang J, Fan L, Liao X, Cui G, Hu H. CRTAC1 (cartilage acidic protein 1) inhibits cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) process in bladder cancer by downregulating Yin Yang 1 (YY1) to inactivate the TGF-β pathway. Bioengineered. 2021;12(2):9377-9389.
Picariello T, Valentine MS, Yano J, Van Houten J. Reduction of meckelin leads to general loss of cilia, ciliary microtubule misalignment and distorted cell surface organization. Cilia. 2014;3(1).
Du E, Zhang C, Qin Z, et al. Low expression of TMEM67 is a critical predictor of poor prognosis in human urothelial carcinoma of the bladder. Urol Oncol. 2017;35(4):152.e7-152.e12.
Qiu X, Cheng JC, Klausen C, Chang HM, Fan Q, Leung PCK. EGF-induced Connexin43 negatively regulates cell proliferation in human ovarian cancer. J Cell Physiol. 2016;231(1):111-119.
Qiu X, Cheng JC, Zhao J, Chang HM, Leung PCK. Transforming growth factor-β stimulates human ovarian cancer cell migration by up-regulating connexin43 expression via Smad2/3 signaling. Cell Signal. 2015;27(10):1956-1962.
Ribeiro CM, Brito LGO, Benetti-Pinto CL, Teixeira JC, Yela DA. Is diagnostic hysteroscopy safe for the investigation of type II endometrial cancer? A retrospective cohort analysis. J Minim Invasive Gynecol. 2021;28(8):1536-1543.
Larish A, Kumar A, Weaver A, Mariani A. Impact of hysteroscopy on course of disease in high-risk endometrial carcinoma. Int J Gynecol Cancer. 2020;30(10):1513-1519.
Dong H, Wang Y, Zhang M, Sun M, Yue Y. Whether preoperative hysteroscopy increases the dissemination of endometrial cancer cells: a systematic review and meta-analysis. J Obstet Gynaecol Res. 2021;47(9):2969-2977.